NeuroPace, Inc. NPCE 深 沪
等待开盘 04-03 09:30:00 美东时间
14.65
+0.580
+4.12%
华盛通- 最 高14.65
- 今 开13.71
- 成交量 17.04万股
- 最 低 13.415
- 昨 收 14.07
- 总市值 4.93亿
- 52周最高 18.975
- 市盈率 静 --
- 换手率 0.51%
- 52周最低 7.5625
- 委 比 -95.04%
- 总股本 3366.69万
- 历史最高 27.38
- 量 比 0.76
- 振 幅 8.78%
- 历史最低 1.22
- 每 手 1
- 风险率 2.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Neuropace shares are trading higher after the company reported better-than-expected Q4 financial results.
Neuropace shares are trading higher after the company reported better-than-expe...
03-04 05:14
NeuroPace Sees FY2026 Sales $98.000M-$100.000M vs $98.943M Est
NeuroPace (NASDAQ:NPCE) sees FY2026 sales of $98.000 million-$100.000 million vs $98.943 million analyst estimate.
03-04 05:08
Earnings Summary: NeuroPace Q4
NeuroPace (NASDAQ:NPCE) reported its Q4 earnings results on Tuesday, March 3, 2...
03-04 05:08
Earnings Scheduled For March 3, 2026
Companies Reporting Before The Bell • On Holding (NYSE:ONON) is expected to rep...
03-03 19:11
Earnings Outlook For NeuroPace
NeuroPace (NASDAQ:NPCE) is preparing to release its quarterly earnings on Tuesd...
03-03 00:01
美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
01-28 10:59
HC Wainwright & Co. Maintains Buy on NeuroPace, Raises Price Target to $19
HC Wainwright & Co. analyst Yi Chen maintains NeuroPace (NASDAQ:NPCE) with a Buy and raises the price target from $18 to $19.
01-27 19:19
2026年展望 | 不止脑机接口！AI巨头开辟医疗“新战场”，这些相关标的值得提前了解
不止脑机接口！AI巨头扎堆布局医疗赛道，技术突破+需求爆发双轮驱动！这22家潜力公司名单抢先看，阿里健康开年已暴涨50%>>
01-14 11:52
NeuroPace Submits Premarket Approval Supplement Application To FDA For Expansion Of Labeled Indication For RNS System
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S) application to the U.S.
2025-12-17 21:04
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
